Greenlight Guru
👤 Jon Speer & David DeRam (Speer: 16+ yrs medtech QA, ran a QMS consultancy, and hosted the field's top podcast - the audience was already his.)🌐 siteLinkedIn
A cloud quality system built only for medical devices - the one tool FDA and ISO force every device maker to buy.
Will it work? · our read
Law forces demand. The FDA and ISO force every device maker to run a QMS. Greenlight Guru didn't create demand - it verticalized a legal mandate and let an insider's podcast do the selling.
01How the money moves
To sell a device, a maker must run an FDA/ISO quality system
→
They adopt Greenlight Guru's pre-built medtech eQMS
→
Pay a 5-figure yearly subscription, renewed at every audit
02The numbers
1,200+
device-maker customers
co. stated
$120M
raised from JMI, 2021
PitchBook
Feb 2026
FDA QMSR takes effect
FDA.gov
The regulation deadline is a demand tailwind, not a headwind. FDA QMSR
Private (PE-backed). Est about $20-30M ARR; $120M raised from JMI (2021).
03Weight class — CENTStap an axis
Control Mid
Owns the medtech audience via its podcast and blog, but still competes in open enterprise sales.
04The key move
Vertical, not horizontal
Rivals sell one QMS to every regulated industry. Greenlight Guru went medtech-only - pre-wiring FDA design controls and ISO 13485 in - and let its founder's podcast, the field's voice, feed the pipeline.
fact
The counter-intuitive move
But vertical caps the ceiling: one horizontal giant bundling a good-enough QMS, or an FDA rule shift, could squeeze the niche's premium.
our read
05Where the moat is
Why a medtech startup can't just switch to a cheaper generic tool:
FDA/ISO workflows built into the productFounder's podcast owns the medtech audienceSystem-of-record data - painful to rip outInsider trust at FDA audit time
06How it diesmedium confidence
It dies if the niche caps it. A horizontal giant (Veeva, MasterControl) bundles a good-enough QMS into a bigger deal, or FDA-ISO harmonization lets generic tools pass audit - erasing the vertical premium. our read
Show evidence · counter
Evidence: 1,200+ paying device-makers and JMI's $120M growth round signal durable, regulation-backed demand.
Counter: But swapping a validated QMS mid-audit is brutal; incumbents are unusually sticky, and QMSR (Feb 2026) only deepens the compliance need.
07Against rivals
Bar = how purpose-built for medical devices (higher = more focused). our read
08Who uses it
MedTech startupsPre-submission device makersSaMD / software-as-device teamsIVD & diagnostics firmsContract device manufacturers
★Would it work for you?
Do you have unfair access to a regulated, high-stakes niche - a domain most builders find boring or scary?
Greenlight Guru won on insider trust, not code. Where do you already have that? We don't score you — you answer.
🚀Use it as a launchpada prompt for your own AI
Copy → paste into your AI → then develop it freely in the conversation.
You are a sharp, honest startup strategist. Use the proven case below as a launchpad for MY idea — help me find my own angle, not copy it.
<my_profile>
Domain I know: [your domain]
My unfair advantage (access/audience): [your edge]
Interests: [your interests]
Resources & goal: [your resources] · [your goal]
</my_profile>
<case name="Greenlight Guru" model="saas">
What it does: A cloud quality-management system built only for medical-device companies, sold as an annual subscription.
Why it won (moat): Domain-deep FDA/ISO workflows plus a founder-owned podcast audience that generalist QMS tools can't match.
Weakest axis (CENTS): Narrow TAM and slow enterprise sales; growth is capped by the size of the medtech market.
How it could die: A horizontal giant bundles a good-enough QMS, or regulatory harmonization lets generic tools pass audit.
</case>
<task>
Be a skeptical operator, not a cheerleader. No generic startup platitudes. If my angle is weak, say so plainly.
First, a reality check: markets like this mostly fail. State the honest base rate (how crowded/hard is this?) and the ONE specific thing that would have to be true for ME to be the exception — grounded in my profile above.
Then a compact table:
- Fit — does this pattern suit my edge, or fight my gap?
- Angle — my sharpest differentiation vs Greenlight Guru (concrete, not "better UX")
- Distribution — exactly where my first 100 users come from (this is the hardest part — be specific, not "content marketing")
- Risk — its "how it dies" (above) in MY situation
Finish with one line: "The single thing to do next."
Use only the facts above; if data is thin, say so — never invent numbers.
Then stay with me and go deeper on whatever I ask — tech stack, rough cost & time, the smallest MVP to test, pricing, or timing.
</task>
✓ Copied — paste into your AI
👤Placeholders like [your domain] auto-fill from your profile — example values for now.Set up profile →
Sourcesupdated · daily
FDA - Quality Management System Regulation (QMSR) - the law that forces the demand; effective Feb 2, 2026.Covington - FDA finalizes QMSR, harmonizing 21 CFR 820 with ISO 13485.Global Medical Device Podcast - the founder-hosted content engine behind distribution.Company history - founded 2013; $120M from JMI; 1,200+ customers (Oct 2023).Latka - third-party revenue estimate (unverified; figures vary widely).
Revenue is EST, not disclosed: Greenlight Guru is private (PE-backed by JMI) and publishes no ARR. Third-party trackers disagree wildly - Latka about $16M, Zippia about $21M, Growjo about $33M - so treat "about $20-30M" as a rough band, not a fact. The only first-party numbers are disclosed funding ($120M from JMI, 2021) and 1,200+ customers (company-stated, Oct 2023). The vertical-only focus and founder-hosted podcast are documented facts; the bundling / FDA-ISO-harmonization death scenario is our read [infer], not a reported event. No drama fabricated. We never score you.